Sutro Biopharma (STRO) Net Margin (2017 - 2025)
Historic Net Margin for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to 586.58%.
- Sutro Biopharma's Net Margin fell 139600.0% to 586.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 219.44%, marking a year-over-year decrease of 1384500.0%. This contributed to the annual value of 366.68% for FY2024, which is 2972100.0% down from last year.
- Latest data reveals that Sutro Biopharma reported Net Margin of 586.58% as of Q3 2025, which was down 139600.0% from 18.04% recorded in Q2 2025.
- In the past 5 years, Sutro Biopharma's Net Margin registered a high of 27.31% during Q4 2023, and its lowest value of 1146.05% during Q1 2025.
- For the 5-year period, Sutro Biopharma's Net Margin averaged around 351.03%, with its median value being 362.83% (2021).
- Per our database at Business Quant, Sutro Biopharma's Net Margin surged by 4280700bps in 2023 and then crashed by -6985400bps in 2025.
- Over the past 5 years, Sutro Biopharma's Net Margin (Quarter) stood at 357.85% in 2021, then decreased by -12bps to 400.76% in 2022, then skyrocketed by 107bps to 27.31% in 2023, then tumbled by -1892bps to 489.43% in 2024, then fell by -20bps to 586.58% in 2025.
- Its Net Margin stands at 586.58% for Q3 2025, versus 18.04% for Q2 2025 and 1146.05% for Q1 2025.